Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of carrelizumab in malignant tumors
ChiCTR2000032979Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Guangxi Medical University
- Start
- Mar 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab in Non-hematologic malignancy, sponsored by The First Affiliated Hospital of Guangxi Medical University. Primary endpoints: progression-free survival and adverse event rate. Planned start Mar 2021; status: not yet recruiting.
02
Drugs
camrelizumab
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on ChiCTR2000032979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000032979.